Suchergebnisse - "Wolchok, Jedd"

Cancer immunotherapy using checkpoint blockade von Ribas, Antoni, Wolchok, Jedd D

“… The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting …”
Weitere Angaben

The many faces of the anti-COVID immune response von Vardhana, Santosha A, Wolchok, Jedd D

“… The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a …”
Weitere Angaben

Clinical implications of T cell exhaustion for cancer immunotherapy von Chow, Andrew, Perica, Karlo, Klebanoff, Christopher A, Wolchok, Jedd D

“… Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T cells are pivotal to the efficacy of current cancer immunotherapies, …”
Volltext

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations von Zou, Weiping, Wolchok, Jedd D, Chen, Lieping

“… PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable antitumor responses and long-term remissions in a subset of …”
Weitere Angaben

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies von Zappasodi, Roberta, Merghoub, Taha, Wolchok, Jedd D

“… Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of …”
Weitere Angaben

PD-1 Blockers von Wolchok, Jedd D

“… Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific …”
Weitere Angaben

Targeting T Cell Co-receptors for Cancer Therapy von Callahan, Margaret K, Postow, Michael A, Wolchok, Jedd D

“… Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the …”
Weitere Angaben

Immune Checkpoint Blockade in Cancer Therapy von Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D

“… Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 …”
Weitere Angaben

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways von Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D, Merghoub, Taha

“… The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as …”
Volltext

Immunotherapy of Melanoma: Facts and Hopes von Weiss, Sarah A, Wolchok, Jedd D, Sznol, Mario

“… Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines, and cell …”
Weitere Angaben

The future of cancer immunotherapy: microenvironment-targeting combinations von Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.

“… Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary …”
Volltext

Checkpoint blockade: the end of the beginning von Wolchok, Jedd D

“… The early 2000s saw the first trials of checkpoint inhibitors in humans. Here, Jedd Wolchok discusses the first clinical results …”
Volltext

The hallmarks of successful anticancer immunotherapy von Galluzzi, Lorenzo, Chan, Timothy A, Kroemer, Guido, Wolchok, Jedd D, López-Soto, Alejandro

“… Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and …”
Weitere Angaben

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy von Callahan, Margaret K., Wolchok, Jedd D.

“… Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in …”
Volltext

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies von Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica

“… Key Points The emergence of cancer immunotherapy has revolutionized cancer treatment but is associated with serious immune-related adverse effects (IRAEs) …”
Volltext

TNF in the era of immune checkpoint inhibitors: friend or foe? von Chen, Allen Y, Wolchok, Jedd D, Bass, Anne R

“… Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care …”
Volltext

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies von Zappasodi, Roberta, Merghoub, Taha, Wolchok, Jedd D

Weitere Angaben

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy von Khalil, Danny N., Smith, Eric L., Brentjens, Renier J., Wolchok, Jedd D.

“… Key Points Cancer immunotherapies have the potential to generate robust antitumour responses; this can be achieved through several methods, such as modulatory …”
Volltext

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner von Holmgaard, Rikke B., Zamarin, Dmitriy, Li, Yanyun, Gasmi, Billel, Munn, David H., Allison, James P., Merghoub, Taha, Wolchok, Jedd D.

“… Indoleamine 2,3-dioxygenase (IDO) has been described as a major mechanism of immunosuppression in tumors, though the mechanisms of this are poorly understood …”
Volltext

Antibody therapy of cancer von Scott, Andrew M., Wolchok, Jedd D., Old, Lloyd J.

“… Key Points Antibody-based therapy for cancer has become established over the past 15 years and is now one of the most successful and important strategies for …”
Volltext